Platforms
STAR-TTM Cell Therapy Platform
BriSTAR Immunotech’s STAR-T platform boasts significant advantages over traditional CAR-T products in treating tumors. STAR-T engages, like CAR-T, tumor antigens independently of human leukocyte antigen (HLA), and offers a multi-pronged option to target solid tumors, including sensitive tumor antigen engagement, ability to engage multiple tumor targets, minimizing tumor antigen escape and enhanced tumor infiltration.
-
-
STAR structure resembles TCR, superior to CAR-T
See details about STAR-TSTAR-T platformSTAR-T platform
STAR (Synthetic T cell receptor and Antigen Receptor) - T, developed by the scientific team at BriSTAR Immunotech, is a TCR-like structure designed to engage tumor antigens more sensitively and to kill tumor cells more effectively. STAR design, inspired by the structure and function of TCR, combines the power of HLA-independent tumor targeting of CAR-T (Chimeric Antigen Receptor T-Cells) with the exquisite antigen engagement capability of TCR-T (T cell receptor engineered T-cells) to potentially achieve better tumor killing and safety profile. The signaling capacity of STAR is further enhanced by the addition of the co-stimulatory domain derived from OX40 receptor to the intracellular terminus of the TCR chain.
Off-the-shelf STAR-T Platform
Off-the-shelf STAR-T Platform adopts the CRISPR-Cas9 gene-editing system and adeno-associated virus (AAV)-mediated site-specific integration strategy, which eliminates the risk of random genomic insertion and improves product safety. Meanwhile, it mitigates graft-versus-host disease (GVHD) and host-versus-graft reaction (HVGR) risks of universal products, enhances the cells’ resistance to immunosuppression and cytotoxicity, and features a clear drug development prospect.
-
-
Off-the-shelf STAR-T Technology Using One-Step Site-Specific Integration
See details about Off-the-shelf STAR-TSTAR-T platformOff-the-shelf STAR-T Platform
The off-the-shelf site-specific integration technology for STAR-T leverages CRISPR-Cas9 gene editing and AAV vector-mediated site-specific integration strategies. It can reduce the product cost to the ten-thousand-yuan level, significantly improving patient accessibility. The clinical research results of its core product—the CD19-targeted off-the-shelf STAR-T (YTS109)—have been published in Nature Medicine.
In vivo STAR-T Platform
Bristar Immunotech's In vivo STAR-T Technology Platform is built on the core STAR-T structure and integrates proprietary technologies for in vivo delivery and in situ modification. It is a disruptive technology platform that accomplishes T cell engineering directly in vivo, eliminating the need for ex vivo cell preparation and patient leukapheresis.
-
-
In vivo STAR-T: Safer In vivo CAR-T
See details about In vivo STAR-TSTAR-T platformIn vivo STAR-T Platform
STAR features outstanding safety and functions exclusively in T cells.The STAR structure retains the TCR structure to the fullest extent.Restricted target interaction: It only recognizes and binds to specific molecules on the surface of T cells (e.g., CD3), and does not bind to other immune cells or normal tissue cells.Dependent functional activation: It only initiates signaling pathways inside T cells to trigger effects such as proliferation and activation, and exerts no regulatory effects on non-T cells.